Cadila’s shares hit 52 week high on vaccine development news


After Zydus Cadila announced phase 3 clinical trials of its experimental COVID-19 vaccine, Cadila Healthcare’s share price nudged a 52 week high in early trade today. The stock opened with a gain of 4.42%, it touched an intraday high scaling to Rs 452 rising with 7.13%. The company is about to launch it’s vaccine by March next year.  

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More